Skip to main content
Top
Published in: BMC Nephrology 1/2024

Open Access 01-12-2024 | IgA Vasculitis | Research

Characteristics of renal pathology and coagulation function in IgA nephropathy and IgA vasculitis associated nephritis

Authors: Yinhong Wang, Hao Wang, Xiaotao Ma, Zikun Zhu, Xuefei Tian, Rongguo Fu, Lining Jia

Published in: BMC Nephrology | Issue 1/2024

Login to get access

Abstract

Background

The objective of this study is to investigate the clinical and pathological differences between patients with IgA nephropathy (IgAN) and IgA vasculitis associated nephritis (IgAVN).

Methods

A total of 253 patients with IgAN and 71 patients with IgAVN were retrospectively included in the study, and clinical and laboratory data were collected and analysed.

Results

Compared with IgAVN group, months from onset to kidney biopsy were significantly prolonged in IgAN patients because of the lack of obvious symptoms such as rash, abdominal symptoms, and joint pain (13.5 ± 26.6 vs. 10.2 ± 31.6 months, P = 0.007), and the levels of serum creatinine (92.3 ± 94.7 vs. 68.9 ± 69.2 µmol/L, P = 0.015) was higher and eGFR (99.1 ± 35.2 vs. 123.4 ± 41.8 mL/min/1.73m2, P < 0.001) was lower in IgAN group. The pathological results revealed that patients with IgAN have a greater degree of chronic kidney injury compared to patients with IgAVN. In addition, the levels of plasma D-Dimers (1415.92 ± 1774.69 vs. 496.78 ± 711.91 ng/mL, P < 0.001) and fibrinogen degradation products (FDP) (3.92 ± 4.73 vs. 1.63 ± 2.46 µg/mL, P = 0.001) were significantly higher in IgAVN patients than in IgAN patients. The deposition of fibrinogen in the renal tissues was more severe and the cumulative partial remission rate was higher in patients with IgAVN as compared to those with IgAN (P = 0.001).

Conclusions

In comparison, IgAN patients had poorer renal function, whereas IgAVN patients had more severe coagulation abnormalities. These findings provide a basis for the differentiation of the two diseases at an early stage.
Appendix
Available only for authorised users
Literature
2.
go back to reference Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.CrossRefPubMed Lai KN, Tang SC, Schena FP, Novak J, Tomino Y, Fogo AB, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.CrossRefPubMed
4.
go back to reference Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5.CrossRefPubMed Suzuki H, Yasutake J, Makita Y, Tanbo Y, Yamasaki K, Sofue T, et al. IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis. Kidney Int. 2018;93(3):700–5.CrossRefPubMed
5.
go back to reference Kung VL, Avasare R, Friedman MA, Koon SM, Neff TL, Protzek S, et al. Targeted transcriptional analysis of IgA Vasculitis, IgA Nephropathy, and IgA-Dominant infection-related glomerulonephritis reveals both distinct and overlapping Immune signatures. Kidney360. 2023;4(6):e759–e68.CrossRefPubMedPubMedCentral Kung VL, Avasare R, Friedman MA, Koon SM, Neff TL, Protzek S, et al. Targeted transcriptional analysis of IgA Vasculitis, IgA Nephropathy, and IgA-Dominant infection-related glomerulonephritis reveals both distinct and overlapping Immune signatures. Kidney360. 2023;4(6):e759–e68.CrossRefPubMedPubMedCentral
6.
go back to reference He Z, Zhang Y, Cao M, Ma R, Meng H, Yao Z, et al. Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy. Nephrol Dial Transplant. 2016;31(5):747–59.CrossRefPubMed He Z, Zhang Y, Cao M, Ma R, Meng H, Yao Z, et al. Increased phosphatidylserine-exposing microparticles and their originating cells are associated with the coagulation process in patients with IgA nephropathy. Nephrol Dial Transplant. 2016;31(5):747–59.CrossRefPubMed
7.
go back to reference Demir S, Yet I, Sardan Ekiz M, Sag E, Bilginer Y, Celikbicak O et al. Plasma proteomic analysis reveals the potential role of Lectin and Alternative Complement pathways in IgA Vasculitis Pathogenesis. Diagnostics (Basel). 2023;13(10). Demir S, Yet I, Sardan Ekiz M, Sag E, Bilginer Y, Celikbicak O et al. Plasma proteomic analysis reveals the potential role of Lectin and Alternative Complement pathways in IgA Vasculitis Pathogenesis. Diagnostics (Basel). 2023;13(10).
8.
go back to reference Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.CrossRefPubMed Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69(5):798–806.CrossRefPubMed
9.
go back to reference Jiang L, Liu G, Lv J, Huang C, Chen B, Wang S, et al. Concise semiquantitative histological scoring system for immunoglobulin A nephropathy. Nephrol (Carlton). 2009;14(6):597–605.CrossRef Jiang L, Liu G, Lv J, Huang C, Chen B, Wang S, et al. Concise semiquantitative histological scoring system for immunoglobulin A nephropathy. Nephrol (Carlton). 2009;14(6):597–605.CrossRef
10.
go back to reference Lv Y, Fu R, Peng XJ, Wang Y, Yin TT, Deng YQ. Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children. BMC Pediatr. 2023;23(1):423.CrossRefPubMedPubMedCentral Lv Y, Fu R, Peng XJ, Wang Y, Yin TT, Deng YQ. Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children. BMC Pediatr. 2023;23(1):423.CrossRefPubMedPubMedCentral
12.
go back to reference Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–36.CrossRefPubMedPubMedCentral Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86(4):828–36.CrossRefPubMedPubMedCentral
13.
go back to reference Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.CrossRefPubMed Stamellou E, Seikrit C, Tang SCW, Boor P, Tesař V, Floege J, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9(1):67.CrossRefPubMed
14.
go back to reference Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29–40.CrossRefPubMed Lutz J, Menke J, Sollinger D, Schinzel H, Thürmel K. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014;29(1):29–40.CrossRefPubMed
15.
go back to reference Troyanov S, Hladunewich MA, Reich HN. How should Pathology findings Influence Treatment in IgA Nephropathy? Kidney Int Rep. 2022;7(1):3–5.CrossRefPubMed Troyanov S, Hladunewich MA, Reich HN. How should Pathology findings Influence Treatment in IgA Nephropathy? Kidney Int Rep. 2022;7(1):3–5.CrossRefPubMed
16.
go back to reference Hahn D, Hodson EM, Craig JC. Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst Rev. 2023;2(2):Cd005128.PubMed Hahn D, Hodson EM, Craig JC. Interventions for preventing and treating kidney disease in IgA vasculitis. Cochrane Database Syst Rev. 2023;2(2):Cd005128.PubMed
17.
go back to reference Wakabayashi I, Masuda H. Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus. J Thromb Thrombolysis. 2009;27(1):29–35.CrossRefPubMed Wakabayashi I, Masuda H. Association of D-dimer with microalbuminuria in patients with type 2 diabetes mellitus. J Thromb Thrombolysis. 2009;27(1):29–35.CrossRefPubMed
18.
go back to reference Yu G, Jiang Y, Xu Z, Cheng J, Li H, Li X, et al. Plasma D-dimer as a potential predictor of progression in IgA nephropathy: a cohort study. Ren Fail. 2023;45(2):2251587.CrossRefPubMedPubMedCentral Yu G, Jiang Y, Xu Z, Cheng J, Li H, Li X, et al. Plasma D-dimer as a potential predictor of progression in IgA nephropathy: a cohort study. Ren Fail. 2023;45(2):2251587.CrossRefPubMedPubMedCentral
19.
go back to reference Nie YL, Song ZX, Tao J, Han X, Yang L. Correlations of serological markers with development of systemic involvement in adult immunoglobulin a vasculitis: a retrospective study of 259 patients in Central China. Curr Med Sci. 2021;41(5):888–93.CrossRefPubMed Nie YL, Song ZX, Tao J, Han X, Yang L. Correlations of serological markers with development of systemic involvement in adult immunoglobulin a vasculitis: a retrospective study of 259 patients in Central China. Curr Med Sci. 2021;41(5):888–93.CrossRefPubMed
20.
go back to reference Mosakowska M, Kania DB, Szamotulska K, Rymarz A, Niemczyk S. Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies. BMC Nephrol. 2021;22(1):290.CrossRefPubMedPubMedCentral Mosakowska M, Kania DB, Szamotulska K, Rymarz A, Niemczyk S. Assessment of the correlation of commonly used laboratory tests with clinical activity, renal involvement and treatment of systemic small-vessel vasculitis with the presence of ANCA antibodies. BMC Nephrol. 2021;22(1):290.CrossRefPubMedPubMedCentral
21.
go back to reference Sörensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011;80(10):1035–44.CrossRefPubMed Sörensen I, Susnik N, Inhester T, Degen JL, Melk A, Haller H, et al. Fibrinogen, acting as a mitogen for tubulointerstitial fibroblasts, promotes renal fibrosis. Kidney Int. 2011;80(10):1035–44.CrossRefPubMed
22.
go back to reference Qin A, Wang S, Dong L, Jiang Z, Yang D, Tan J et al. Prognostic value of the albumin-to-fibrinogen ratio (AFR) in IgA nephropathy patients. Int Immunopharmacol. 2022;113(Pt A):109324. Qin A, Wang S, Dong L, Jiang Z, Yang D, Tan J et al. Prognostic value of the albumin-to-fibrinogen ratio (AFR) in IgA nephropathy patients. Int Immunopharmacol. 2022;113(Pt A):109324.
23.
go back to reference Wang F, Huang L, Tang H, Li X, Zhu X, Wang X. Significance of glomerular fibrinogen deposition in children with Henoch-Schönlein purpura nephritis. Ital J Pediatr. 2018;44(1):97.CrossRefPubMedPubMedCentral Wang F, Huang L, Tang H, Li X, Zhu X, Wang X. Significance of glomerular fibrinogen deposition in children with Henoch-Schönlein purpura nephritis. Ital J Pediatr. 2018;44(1):97.CrossRefPubMedPubMedCentral
24.
go back to reference Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of henoch-schönlein purpura in children. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):39–47.CrossRefPubMedPubMedCentral Hong J, Yang HR. Laboratory markers indicating gastrointestinal involvement of henoch-schönlein purpura in children. Pediatr Gastroenterol Hepatol Nutr. 2015;18(1):39–47.CrossRefPubMedPubMedCentral
Metadata
Title
Characteristics of renal pathology and coagulation function in IgA nephropathy and IgA vasculitis associated nephritis
Authors
Yinhong Wang
Hao Wang
Xiaotao Ma
Zikun Zhu
Xuefei Tian
Rongguo Fu
Lining Jia
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2024
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-024-03465-6

Other articles of this Issue 1/2024

BMC Nephrology 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.